We are live on ! Find out more
KM

Kalos Management Portfolio holdings

AUM $46.6M
1-Year Est. Return 11.52%
This Fund
S&P 500
This Quarter Est. Return
+9.04%
1 Year Est. Return
+11.52%
3 Year Est. Return
+48.48%
5 Year Est. Return
+71.6%
10 Year Est. Return
AUM
$274M
AUM Growth
+$23.5M
Cap. Flow
+$3.11M
Cap. Flow %
1.13%
Top 10 Hldgs %
24.38%
Holding
231
New
32
Increased
50
Reduced
100
Closed
27

Sector Composition

Rank Sector Weight
1 Technology 10.51%
2 Healthcare 8.02%
3 Financials 7.07%
4 Industrials 4.96%
5 Consumer Discretionary 3.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PARA
176
DELISTED
Paramount Global Class B
PARA
$229K 0.08%
+5,443
New +$211K
FDX icon
177
FedEx
FDX
$74B
$225K 0.08%
1,453
-294
-17% -$45.3K
IEFA icon
178
iShares Core MSCI EAFE ETF
IEFA
$187B
$223K 0.08%
+3,424
New +$217K
IOVA icon
179
Iovance Biotherapeutics
IOVA
$2.1B
$221K 0.08%
+8,150
New +$185K
CVX icon
180
Chevron
CVX
$374B
$213K 0.08%
1,772
BAC icon
181
Bank of America
BAC
$439B
$209K 0.08%
+5,902
New +$191K
VTV icon
182
Vanguard Value ETF
VTV
$190B
$200K 0.07%
+1,671
New +$193K
VKQ icon
183
Invesco Municipal Trust
VKQ
$541M
$183K 0.07%
14,750
AUY
184
DELISTED
Yamana Gold, Inc.
AUY
$182K 0.07%
46,228
-1,115
-2% -$3.92K
MAV
185
DELISTED
Pioneer Municipal High Income Advantage Fund
MAV
$177K 0.06%
16,400
NGNE icon
186
Neurogene
NGNE
$663M
$177K 0.06%
728
-17
-2% -$1.69K
GYRE icon
187
Gyre Therapeutics
GYRE
$668M
$121K 0.04%
2,441
CLVS
188
DELISTED
Clovis Oncology, Inc.
CLVS
$114K 0.04%
+11,050
New +$80.4K
ENBL
189
DELISTED
ENABLE MIDSTREAM PARTNERS, LP
ENBL
$102K 0.04%
10,220
-1,638
-14% -$16.7K
PRTK
190
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$100K 0.04%
25,050
FOLD
191
DELISTED
Amicus Therapeutics
FOLD
$98K 0.04%
10,150
-700
-6% -$6.41K
UDF
192
DELISTED
UNITED DEV FDG IV COM SHS OF BENE INT (TX)
UDF
$91K 0.03%
33,644
+280
+0.8% +$757
EXK
193
Endeavour Silver
EXK
$2.29B
$89K 0.03%
37,299
-952
-2% -$2.16K
PSLV icon
194
Sprott Physical Silver Trust
PSLV
$11.7B
$80K 0.03%
12,367
CTSO icon
195
Cytosorbents Corp
CTSO
$23.3M
$52K 0.02%
13,500
HTGM
196
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$48K 0.02%
372
SACH
197
Sachem Capital Corp
SACH
$38.8M
$47K 0.02%
11,000
VSTM icon
198
Verastem
VSTM
$547M
$39K 0.01%
2,438
+1,355
+125% +$19.5K
PFX icon
199
PhenixFIN
PFX
$83M
$29K 0.01%
675
HSTO
200
DELISTED
Histogen Inc. Common Stock
HSTO
$16K 0.01%
208
-30
-13% -$2.1K

Similar funds

Kalos Management's Q4 2019 Portfolio in Review

As of Q4 2019, Kalos Management held 231 positions worth $274M, up 9.4% from $251M the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Kalos Management's Q4 2019 filing shows 32 new, 50 increased, 100 reduced and 27 closed positions. Its largest new stake was Vanguard S&P 500 ETF: 13,058 shares worth $3.87M. The largest sale was iShares US Real Estate ETF, an estimated $4.27M.

By sector, the portfolio is most concentrated in Technology at 11% of assets, up from 10% a quarter earlier, followed by Healthcare and Financials.

  • Kalos Management's largest Q4 2019 buy was Vanguard S&P 500 ETF: 13,058 shares worth $3.87M.
  • Kalos Management added most to iShares S&P 500 Value ETF in Q4 2019, an estimated $5.52M increase.
  • Kalos Management's biggest Q4 2019 reduction was iShares US Real Estate ETF, cutting an estimated $4.27M.
  • Kalos Management fully exited CRH in Q4 2019, selling an estimated $3.19M.
  • Kalos Management's ten largest holdings make up 24% of its $274M portfolio in Q4 2019.
  • Kalos Management opened 32 new positions and closed 27 in Q4 2019.
  • Kalos Management's portfolio value rose 9.4% quarter-over-quarter to $274M.

Based on Kalos Management's 13F filing for Q4 2019, filed 13 Feb 2020.